How effective is Verzenio?
- Verzenio plus endocrine therapy (ET) decreases the risk of breast cancer recurrence by 35% compared to ET alone. 4-year data from the monarchE trial showed 85.5% of patients remained recurrence-free after 4 years compared to 78.6% of those assigned ET alone (an absolute difference of 6.9%).
- Women taking Verzenio plus an aromatase inhibitor experienced a longer progression-free survival than those taking a placebo (28.2 months compared to 14.8 months).
- 55% of women experienced a complete or partial response to Verzenio plus an aromatase inhibitor.
- Women taking Verzenio plus fulvestrant were less likely to experience an “event” that impacted their disease progression (49.8% vs 70.4%).
- For women taking Verzenio as monotherapy, 19.7% saw their tumors shrink by 30% or more.
Verzenio (abemaciclib) is a targeted treatment that helps to reduce the growth and spread of cancer cells in the body. It may be used to treat men or women with hormone receptor-positive, HER2-negative (HR+ HER2-), node-positive, early breast cancer at high risk of recurrence. It is also approved for HR+ HER2- advanced or metastatic breast cancer in men or women. Verzenio may be given when cancer has progressed or spread to other parts of the body after treatments such as anti-estrogens or chemotherapy have already been given.
Verzenio belongs to the class of medicines known as CDK 4/6 inhibitors which help to reduce the growth and spread of cancer cells in the body.
Clinical trials have shown favorable results for men or women with early breast cancer and high-risk clinical and pathological factors taking Verzenio plus tamoxifen or ET.
- There was a deepened benefit in invasive disease-free survival in those taking Verzenio in combination with ET compared to those taking ET alone, in a follow-up of the monarchE trial at 4 years compared to the results seen at 2 years. 85.5% of patients remained recurrence-free after 4 years compared to 78.6% of those assigned ET alone (an absolute difference of 6.9%). At 2 years the absolute difference was 3.1% and at 3 years it was 5.0%. Verzenio plus ET reduces the risk of recurrence by 35% compared to ET alone.
- There was a statistically significant improvement in invasive disease-free survival for a pre-specified subgroup of patients (those with a Ki-67 score ≥20%) receiving Verzenio plus endocrine therapy (ET) compared to those who received ET alone (HR=0.643, 95% CI: 0.475, 0.872, p=0.0042)
- There was a 37% decrease in the risk of breast cancer recurrence or death compared to standard ET therapy alone (HR: 0.626 [95% CI: 0.49-0.80])
- An absolute benefit in invasive disease-free survival (IDFS) rate of 7.1% was reported at three years
- Preliminary results reported the number of IDFS events at the time of publication was 104 with Verzenio plus ET compared to 158 with ET alone.
For women taking Verzenio plus anastrozole or letrozole:
- Progression-free survival (the length of time without a worsening of their breast cancer) was longer with Verzenio: 28.2 months for women taking the Verzenio combination compared with 14.8 months for women taking the placebo combination
- 55.4% of women taking the Verzenio combination had either a complete response or a partial response compared to only 40.2% taking a placebo.
For women taking Verzenio in combination with fulvestrant:
- Fewer women experienced an “event” that impacted their progression-free survival: 49.8% of women taking Verzenio experienced an event compared to 70.4% of those taking the placebo combination
- Overall survival was 46.7 months in women taking the Verzenio combination compared with 37.3 months in those taking the placebo combination
- 48.1% of women responded to the Verzenio combination compared with 21% of women taking the placebo combination.
For women taking Verzenio as monotherapy:
- 19.7% of women saw their tumors shrink by 30% or more
- The average duration of response was 8.6 months.
Verzenio is usually taken twice daily. When taken regularly, consistent blood levels are achieved within five days. Gastrointestinal side effects, such as diarrhea, typically occur in the first month of treatment and can affect up to 81% of patients. The average time to onset of diarrhea was 6 to 8 days. Diarrhea can be severe and requires monitoring and proper management.
Related questions
- How long do you take Verzenio for?
- Is Verzenio better than Ibrance?
- Can you take Verzenio after Ibrance fails?
Who can use Verzenio?
Verzenio is indicated for the treatment of HR+ HER2- early breast cancer at high risk of recurrence in combination with endocrine treatment (tamoxifen or an aromatase inhibitor). It may also be used to treat HR+ HER2- advanced or metastatic breast cancer:
- in combination with an aromatase inhibitor for postmenopausal women, and men, as initial endocrine-based therapy
- in combination with fulvestrant for adult patients with disease progression following endocrine therapy
- as a single agent for adult patients with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
References
- Verzenio (abemaciclib) Updated 03/2023. Eli Lilly and Company https://www.drugs.com/pro/verzenio.html
- Verzenio (abemaciclib). 2023. Eli Lilly and Company. https://www.verzenio.com
Read next
How long does it take Verzenio to work?
Although Verzenio starts inhibiting CDK4/6 enzymes quickly, it may take up two to four months before any change in outcomes, such as progression-free survival, are noted. Side effects, such as diarrhea usually occur within the first week or month of treatment. Verzenio reaches consistent blood levels within five days of taking it twice a day.
Continue reading
Is Verzenio (abemaciclib) a chemo drug?
Verzenio is considered a targeted treatment, rather than being a chemo drug, but it may be used to treat certain types of breast cancer. Verzenio belongs to the class of medicines known as CDK 4/6 inhibitors which help to reduce the growth and spread of cancer cells in the body. Continue reading
What type of drug is Verzenio?
Verzenio (abemaciclib) is a small molecule drug and kinase inhibitor used to treat patients with early breast cancer, and advanced or metastatic breast cancer. It is used to treat both men and women. Verzenio is an ATP-competitive inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4 and CDK6). Continue reading
Related medical questions
- What is the strongest chemotherapy drug for breast cancer?
- Why are my nipples sore? 7 possible causes
- How long do letrozole side effects last?
- What happens when you stop taking letrozole?
- What is the success rate of Keytruda?
- Does anastrozole cause hair loss?
- How do you relieve joint pain associated with tamoxifen or Aromasin?
- How long does Ibrance extend life?
- What is the TC chemo regimen and how does it treat breast cancer?
- Is letrozole a form of chemotherapy?
- What does anastrozole do to your body?
- What are monoclonal antibodies?
- What is the success rate of Enhertu in metastatic breast cancer?
- What is the lifetime or cumulative dose for Adriamycin?
- Does Femara make your hair fall out?
- Why give Taxol (Paxel) before carboplatin?
- What is Herceptin? Is Herceptin a chemo drug? How does it work?
- Does letrozole affect blood sugar levels?
- How does Adriamycin and Cytoxan (AC chemo) work for Breast Cancer?
- Will insurance pay for the cost of Ibrance?
- What is the success rate for Femara in breast cancer?
- What are 10 key Ibrance side effects to watch out for?
- Treatments for Menopause
- What is TCHP chemotherapy and how is it used?
- What are the long-term side effects of Adriamycin?
- Why do you need to take Xeloda with food?
- Is it common to lose hair AFTER stopping tamoxifen?
- Which is better - Aromasin or Femara?
- How long can you stay on Herceptin and Perjeta?
Drug information
Related support groups
- Verzenio (9 questions, 15 members)
- Abemaciclib (6 questions, 6 members)
- Breast Cancer (129 questions, 310 members)